Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 231.13% from the stock's current price.

A number of other brokerages have also recently weighed in on NTLA. Guggenheim dropped their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Truist Financial reduced their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Wedbush reissued a "neutral" rating and set a $10.00 target price on shares of Intellia Therapeutics in a research note on Monday. Finally, The Goldman Sachs Group restated a "sell" rating and set a $9.00 price target on shares of Intellia Therapeutics in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.90.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $9.06 on Tuesday. The company's 50 day simple moving average is $7.98 and its 200-day simple moving average is $10.68. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The company has a market capitalization of $938.46 million, a price-to-earnings ratio of -1.67 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same quarter in the prior year, the firm posted ($1.12) EPS. Intellia Therapeutics's quarterly revenue was down 42.6% compared to the same quarter last year. Equities analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc boosted its stake in shares of Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after acquiring an additional 1,100 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock worth $120,000 after buying an additional 1,282 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Intellia Therapeutics by 14.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after buying an additional 1,582 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after buying an additional 1,615 shares during the period. Finally, E Fund Management Co. Ltd. raised its holdings in Intellia Therapeutics by 10.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after acquiring an additional 1,634 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.